论文部分内容阅读
该实验旨在制备丹酚酸组分磷脂复合物的羟基磷灰石(HA)共沉淀物,以提高药物的体外溶出,同时改善丹酚酸组分磷脂复合物的粉体学性质。首先采用溶剂法制备共沉淀物,以丹酚酸组分中的丹酚酸B和丹参素为指标成分考察其体外溶出,同时对其进行粉体学性质的考察,并利用DSC,XRD,FTIR等表征手段对其结构特征进行分析研究。结果可得丹酚酸组分磷脂复合物与羟基磷灰石按1∶2制备的共沉淀物的体外溶出效果较好,60 min时药物的体外累积溶出率达到90%以上;粉体学性质考察结果表明该共沉淀物流动性良好,吸湿性低,粉体学性质得到了较大的改善,微观结构的表征分析表明药物仍旧以非晶形式存在。该实验的制备工艺简单可行,具有实际应用价值。
The purpose of this experiment was to prepare hydroxyapatite (HA) coprecipitates of the phospholipid complex of the salvianolic acid component to improve the dissolution of the drug in vitro and to improve the powdery properties of the phospholipid complex of the salvianolic acid component. First, the coprecipitates were prepared by solvent method. The dissolution of salvianolic acid B and danshensu in salvianolic acid component were investigated in vitro, and the powdering properties were investigated. The results of DSC, XRD, FTIR Such as characterization means of structural analysis. Results The solubilization of coprecipitate prepared by 1: 2 salvianolic acid component phospholipid complex and hydroxyapatite was better than that of hydroxyapatite, and the cumulative dissolution rate of drug was above 90% at 60 min. The powder properties The results show that the coprecipitate has good fluidity, low hygroscopicity and good powder properties, and the characterization of the microstructure shows that the drug still exists in the amorphous form. The preparation process of the experiment is simple and feasible and has practical application value.